{"changeSha256":"7abe191532525e3f42d8a780dcbd9f1ddade1adb7e50d6fa578737f93ccddd99","changedAt":"2026-11-16","changedFields":[{"after":"A 37-amino-acid human cathelicidin peptide, also called ropocamptide, tested in small trials in chronic ulcers. FDA lists it among compounding substances that may present significant safety risks.","before":"A 37-amino-acid human cathelicidin peptide, also called ropocamptide, that FDA lists among compounding substances that may present significant safety risks.","field":"Profile summary"},{"after":"Three small randomized trials in chronic leg and foot ulcers report mixed results; the largest found no significant difference from placebo. FDA states that it lacks sufficient safety information on LL-37 in people. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.","before":"FDA states that it lacks sufficient safety information on LL-37 in people and cites nonclinical findings of harm to male reproduction and tumor promotion. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.","field":"Evidence note"},{"after":"Cathelicidin LL-37, Ropocamptide, LL37","before":"Cathelicidin LL-37, Ropocamptide","field":"Related names"},{"after":"fda-ll-37-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, fda-pcac-503a-meeting-2027, journal-pmid-25041740, journal-pmid-34687253, journal-pmid-37480520, ctg-observation-nct02225366-2021-12-09-d146b413ecf5","before":"fda-ll-37-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","field":"Cited source records"},{"after":"name: fda-ll-37-identity, fda-bulk-peptide-risks; aliases: fda-ll-37-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ll-37-identity, fda-bulk-peptide-risks, journal-pmid-34687253; evidenceNote: journal-pmid-34687253, journal-pmid-25041740, journal-pmid-37480520, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"name: fda-ll-37-identity, fda-bulk-peptide-risks; aliases: fda-ll-37-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ll-37-identity, fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/ll-37/versions/2/","version":2},"id":"profile:ll-37:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added three randomized trials of LL-37 in chronic ulcers, FDA’s advisory committee page listing LL-37 for a meeting before the end of February 2027, and the spelling LL37 that trial registrations use, so that those registrations are matched.","peptideSlugs":["ll-37"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/ll-37/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"journal-pmid-34687253","name":"Wound Repair and Regeneration","sourceClass":"A","title":"Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial (2021) · PMID 34687253","url":"https://doi.org/10.1111/wrr.12977","verifiedAt":"2026-11-16"},{"id":"journal-pmid-25041740","name":"Wound Repair and Regeneration","sourceClass":"A","title":"Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial (2014) · PMID 25041740","url":"https://doi.org/10.1111/wrr.12211","verifiedAt":"2026-11-16"},{"id":"journal-pmid-37480520","name":"Archives of Dermatological Research","sourceClass":"A","title":"Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial (2023) · PMID 37480520","url":"https://doi.org/10.1007/s00403-023-02657-8","verifiedAt":"2026-11-16"},{"id":"fda-pcac-503a-meeting-2027","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · content current as of April 15, 2026","url":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee","verifiedAt":"2026-11-16"}],"subject":{"slug":"ll-37","type":"profile"}}
